Business
Vortex Announces First Commercial VTX-1 Sale
Vortex Announces First Commercial VTX-1 Sale.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 7197V NetScientific PLC 07 November 2017 \n\nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \n \nVortex Biosciences Announces First Commercial Sale of the VTX-1 Liquid Biopsy System\n \nLondon, UK - 7 November 2017 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex BioSciences, today announced its first direct commercial sale of its VTX-1 Liquid Biopsy System, a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs). \n \nVortex's VTX-1 Liquid Biopsy System automates the capture and collection of viable CTCs directly from whole blood for analysis. Circulating tumour cells, which are shed into the circulation, offer researchers new insights into patients' cancer biology. Using proprietary microfluidics technology, the Vortex VTX-1 traps unlabeled CTCs in microscale vortices from whole blood, allowing researchers to perform processes such as whole genome amplification (WGA) and targeted next-generation sequencing (NGS) to better understand cancer progression and potentially develop new methods of disease identification and monitoring.\n \nCommenting on the news, Francois Martelet, Chairman of Vortex BioSciences Inc. and CEO of NetScientific said: \"We are delighted to announce the first sale of Vortex's VTX-1, which represents an important step in the Company's commercialisation journey. The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer. Vortex Biosciences is a core element of NetScientific's portfolio, and we believe the performance of the VTX-1 system and its ease of use, will ensure it emerges as a leader in the highly exciting and rapidly developing CTC field.\" \n \n# # #\n \nFor more information, please contact:\n \n\n\n\n\n NetScientific\n François R. Martelet, M.D., CEO\n Ian Postlethwaite, CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\n \n Consilium Strategic Communications\n Mary-Jane Elliott / Jessica Hodgson /\n Chris Welsh / Laura Thornton \n\n\n \nTel: +44 (0)20 3709 5700\nnetsc...